

First schedule1-10 μ g HBcAg / acemannan 3mg/mL


IN

2-10 μ g HBcAg / PBS 1X

IN


3-10 μ g HBcAg / alum 0.5mg/mL

SC

**Fig. 1**


Second Schedule

| | |
|---|----|
| 1-10 μ g HBsAg/ PBS 1X | IN |
| 2-10 μ g HBsAg/ acemannan 3mg/mL | IN |
| 3-10 μ g HBsAg/ 10 μ g HBcAg / PBS 1X | IN |
| 4-10 μ g HBsAg/ Alum 0.5mg/mL | SC |

**Fig. 2**

Third schedul

| | |
|---------------------------------------|----|
| 1- 5 μ g HBsAg / PBS 1X | IN |
| 2- 5 μ g HBsAg / 5 μ g HBcAg | IN |
| 3- 5 μ g HBsAg / 10 μ g HBcAg | IN |
| 4- 5 μ g HBsAg / 20 μ g HBcAg | IN |
| 5- 5 μ g HBsAg / acemannan 3mg/mL | IN |
| 6- 5 μ g HBsAg / alum 0.5mg/mL | IM |

**Fig. 3**

Fourth Schedule: Synergism at mucosal lev 1.

| | | | | | | | | |
|-------------------|---|---|---|---|---|---|---|---|
| Acemannan 3mg/mL | X | | | X | | X | | |
| HBcAg 5µg/dose | | X | | | X | | X | |
| HBsAg 5µg/dose | X | X | X | | | X | X | |
| VLP /HPV 5µg/dose | X | X | X | X | X | | | X |






Fig. 4 Composition, per groups, in the upper part of the figure.

T.O.T60" 20425860

Fifth Schedule1-10 μ g HCV NC/ PBS 1X


IN

2-5 μ g HBsAg/ PBS 1X

IN

3-10 μ g HBsAg/ 10 μ g HCV NC / PBS 1X

IN

**Fig. 5**